Structure-activity relationships of urotensin II and URP

被引:48
作者
Leprince, Jerome [1 ,2 ,3 ]
Chatenet, David [1 ,2 ,3 ]
Dubessy, Christophe [1 ,2 ,3 ]
Fournier, Alain [3 ,4 ]
Pfeiffer, Bruno [5 ]
Scalbert, Elizabeth [5 ]
Renard, Pierre [5 ]
Pacaud, Pierre [6 ]
Oulyadi, Hassan [1 ,7 ]
Segalas-Milazzo, Isabelle [1 ,7 ]
Guilhaudis, Lauri [1 ,7 ]
Davoust, Daniel [1 ,7 ]
Jonon, Marie-Christine [1 ,2 ,3 ]
Vaudry, Hubert [1 ,2 ,3 ]
机构
[1] Univ Rouen, European Inst Peptide Res IFRMP 23, Mont St Aignan, France
[2] Lab Cellular & Mol Neuroendocrinol, Mont St Aignan, France
[3] Int Associated Lab Samuel de Champlain, Mont St Aignan, France
[4] Univ Quebec, Inst Armand Frappier, INRS, Lab Peptide Pharmacol, Pointe Claire, PQ, Canada
[5] Inst Rech Servier, F-92150 Suresnes, France
[6] Univ Nantes, INSERM, Lab Cellular & Mol Physiopathol & Pharmacol, Nantes, France
[7] Univ Rouen, CNRS, Lab Nucl Magnet Resonance, UMR 6014, Mont St Aignan, France
关键词
urotensin II; urotensin II-related peptide; structure-activity relationship;
D O I
10.1016/j.peptides.2007.08.014
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Urotensin II (U-II) and urotensin II-related peptide (URP) are the endogenous ligands for the orphan G-protein-coupled receptor GPR14 now renamed UT. At the periphery, U-II and/or URP exert a wide range of biological effects on cardiovascular tissues, airway smooth muscles, kidney and endocrine glands, while central administration of U-II elicits various behavioral and cardiovascular responses. There is also evidence that U-II and/or URP maybe involved in a number of pathological conditions including heart failure, atherosclerosis, renal dysfunction and diabetes. Because of the potential involvement of the urotensinergic system in various physiopathological processes, there is need for the rational design of potent and selective ligands for the UT receptor. Structure-activity relationship studies have shown that the minimal sequence required to retain full biological activity is the conserved U-II(4-11) domain, in particular the Cys(5) and Cys(10) residues involved in the disulfide bridge, and the Phe(6), Lys(8) and Tyr(9) residues. Free a-amino group and C-terminal COOH group are not necessary. for the biological activity, and modifications of these radicals may even increase the stability of the analogs. Punctual substitution of native amino acids, notably Phe(6) and Trp(7), by particular residues generates analogs with antagonistic properties. These studies, which provide crucial information regarding the structural and conformational requirements for ligand-receptor interactions, will be of considerable importance for the design of novel UT ligands with increased selectivity, potency and stability, that may eventually lead to the development of innovative drugs. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:658 / 673
页数:16
相关论文
共 105 条
[1]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[2]  
[Anonymous], ADV DRUG RES
[3]   The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems [J].
Behm, David J. ;
Stankus, Gerald ;
Doe, Christopher P. A. ;
Willette, Robert N. ;
Sarau, Henry M. ;
Foley, James J. ;
Schmidt, Dulcie B. ;
Nuthulaganti, Parvathi ;
Fornwald, James A. ;
Ames, Robert S. ;
Lambert, David G. ;
Calo', Girolamo ;
Camarda, Valeria ;
Aiyar, Nambi V. ;
Douglas, Stephen A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (02) :173-190
[4]   Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle [J].
Behm, DJ ;
Ao, ZH ;
Camarda, V ;
Aiyar, NV ;
Johns, DG ;
Douglas, SA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 516 (03) :276-281
[5]   Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice [J].
Behm, DJ ;
Harrison, SM ;
Ao, ZH ;
Maniscalco, K ;
Pickering, SJ ;
Grau, EV ;
Woods, TN ;
Coatney, RW ;
Doe, CPA ;
Willette, RN ;
Johns, DG ;
Douglas, SA .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (02) :464-472
[6]   NMR AND DYNAMICAL SIMULATED ANNEALING STUDIES ON THE SOLUTION CONFORMATION OF UROTENSIN-II [J].
BHASKARAN, R ;
ARUNKUMAR, AI ;
YU, C .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1994, 1199 (02) :115-122
[7]   RELATIONSHIPS BETWEEN CHEMICAL STRUCTURES AND BIOLOGICAL PROPERTIES OF POSTERIOR PITUITARY HORMONES AND THEIR SYNTHETIC ANALOGUES [J].
BOISSONNAS, R ;
GUTTMANN, S ;
KONZETT, H ;
BERDE, B .
EXPERIENTIA, 1961, 17 (09) :377-+
[8]   Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries [J].
Bottrill, FE ;
Douglas, SA ;
Hiley, CR ;
White, R .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (08) :1865-1870
[9]   Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain [J].
Boucard, AA ;
Sauvé, SS ;
Guillemette, G ;
Escher, E ;
Leduc, R .
BIOCHEMICAL JOURNAL, 2003, 370 :829-838
[10]   Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta [J].
Bousette, N ;
Patel, L ;
Douglas, SA ;
Ohlstein, EH ;
Giaid, A .
ATHEROSCLEROSIS, 2004, 176 (01) :117-123